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Summary
Primary hypercalciuria is a highly heterogeneous complex
metabolic disorder and it can be schematically represented
by three general distinct clinical entities, such as absorptive
hypercalciuria, renal hypercalciuria and resorptive hypercal-
ciuria. In fact, other than absorptive hypercalciuria, hypercal-
ciuria has been described in several monogenic syndromes
such as Dent’s disease, Bartter’s Syndrome, Hereditary Hy-
pomagnesaemia-Hypercalciuria Syndrome, hypercalciuric
syndromes due to mutations of calcium sensing receptor
gene such as Familial Hypocalcaemia with Hypercalciuria
Syndrome and Familial Hypercalcemia and Hypercalciuria
Syndrome and in a less common forms of hypophos-
phatemia with hypercalciuria. Of course, environmental fac-
tors influence hypercalciuria, but a strong genetic compo-
nent has been clearly demonstrated. In fact, in many hyper-
calciuric conditions a familial trait has been observed indi-
cating the existence of inherited predisposing gene muta-
tions. Forty to 45% of patients with idiopathic hypercalciuria
exhibit at least one family member with nephrolithiasis. An
apparent autosomal inheritance of hypercalciuria has been
reported as also a clear autosomal recessive transmission in
individual kindreds. Up to date, several genetic defects have
been already identified accounting for familial hypercalci-
uria, but others are still waiting for being unraveled. Howev-
er, the genes responsible for inherited hypercalciuria might
also account for sporadic form, as reported in literature, in-
cluding isolated or incidental hypercalciuria. Here we will
briefly review the more recent evidences accumulated in the
international literature in this fascinating field of human
p a t h o p h y s i o l o g y .
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Introduction
Primary hypercalciuria (PH) is a multifactorial disorder whose
onset depends both on environmental and genetic factors. As
for other complex diseases, such as diabetes, hypertension,
osteoporosis, molecular technologies will be helpful to identify
either the responsible genetic factors or subjects susceptible
to develop such disorders, providing the opportunity for ade-
quate clinical management and therapy. PH is a complex
highly heterogeneous defect of calcium metabolism character-
ized by an elevated urinary excretion of calcium, in the ab-
sence of other alterations. According to Frick and Bushinsky, it
can be caused by a “dysregulation of calcium transport at
sites where large fluxes of calcium must be precisely con-
trolled: these sites are the intestine, kidney and bone” (1).
Generally, it is defined by the occurrence of a urinary calcium
excretion exceeding the threshold values, established in 1957
by Hodgkinson and Pyrah, at 7.5 mmol/24 hours for men and
6.25 mmol/24 hours for women (2). Alternatively, urinary calci-
um may be normalized to body weight and hypercalciuria is
considered as the calcium excretion above 100 mmol/24 hours
per kg of body weight in both sexes (3). Hypercalciuric sub-
jects represent the 5-10% of general population (2,3). Their
presence causes a skewness to high values in the urinary cal-
cium distribution curve, which is more evident in the stone
forming (Figure 1) or osteoporotic populations. The frequency
of hypercalciuria among these patients is higher than usually
found in general population and may involve 20-50% of them
(4,5). Analysis of the calcium excretion distribution curve in
471 stone formers indicates that it better fits a bimodal model
(Figure 1). According to this model, stone formers appear to
be composed by two different subsets of subjects (6). The first
one is composed by 23% of patients, mostly hypercalciurics,
whose calcium excretion can be estimated of 153±48 mm o l /k g
body weight in 24 hours. The other group, mainly composed
by normocalciuric subjects, has an estimated calcium excre-
tion of 85±33 mmol/kg body weight in 24 hours. Overlapping of
calcium excretion curves, representing these subpopulations,
reveals that PH may include subjects with different character-
i s t i c s .
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Genetic dissection of primary hypercalciuria
Familial studies display that calcium excretion is correlated be-
tween sib-pairs, brothers and sisters, parents and children, but
not between spouses (Figure 2) that do not share a common
genetic background. Thus, a great portion of calcium excretion
variability appears to be explained by hereditary factors. The
proportion of calcium excretion variance is indicated by the cor-
relation coefficient in offspring-parents (7). In the considered
families, approximately 50% of the calcium excretion variance
is justified by additive effect of genes (r=0.474, n=63,
p=0.0001, Figure 2). In human pedigrees, hypercalciuria can
be detected at each generation, with a sex independent trans-
mission and no concordance for hypercalciuria in wives and
husbands (8,9). These familial studies considered urinary calci-
um as a qualitative trait with hypercalciuria/normocalciuria as
the only possible phenotypes. In these studies hypercalciuria
inheritance was regarded as an autosomal dominant
Mendelian trait with high penetrance (8,9). However, calcium
excretion is a quantitative trait and its phenotypes are distrib-
uted on a continuous scale (10). Variance of a quantitative trait
is a multigenic parameter involving many alleles singularly ex-
erting a small effect, and hypercalciuria has to be considered
as a polygenic trait with a heterogeneous genetic substrate and
complex pattern of hereditary transmission (11,12). The com-
plexity of this picture is increased by gene-gene and gene-envi-
ronment interactions with reciprocal influences, able to change
substantially the effect of a gene on a phenotype (13). The
search for genetics of hypercalciuria has been aimed to identify
both candidate genes and genetic polymorphisms underlying
the genetic susceptibility for this disorder. Although it cannot be
excluded that polymorphisms in a single gene may be sufficient
to cause hypercalciuria, it is more likely that PH arises when
predisposing alleles, at different loci, together concur to regu-
late urinary calcium excretion. The number of involved loci and
the effect size of alleles may vary according to the role of can-
didate genes in calcium metabolism, to the activity of their dif-
ferent variants and to the gene/s-gene/s interactions (13). A dif-
ferent genetic substrate may be present in the two subpopula-
tions of stone formers identified by the analysis of calcium ex-
cretion distribution: they may be distinguished by the presence
of allele variants at one locus or, more likely, at few loci having
remarkable effects on the phenotype, shifting the mean of the
calcium excretion distribution curve toward higher values (10).
Genetic causes of PH have been approached with different
strategies.
A strain of spontaneously hypercalciuric rats has been ob-
t ined, but the gene/s responsible for the defect has not been
yet found (14). Furthermore, at least three strains of knockout
ats have been selected, respectively not expressing sodium-
phosphate co-transporter, paracellin or caveolin 1, and they
are under investigation (15-17). In humans, familial studies un-
revealed the association between polymorphisms of soluble
ad nilate-cyclase (s A C) gene, located onto chromosome
1q23.3-q24, and hypercalciuria and low bone mass (18), while
he study of calcium sensing receptor (C a S R) gene exhibited
conflictual results (19, 20). Moreover, other genes have been
aken into account, like those of epithelial calcium channel
(EcaC1) or vitamin D receptor (VDR) gene (9,21), but no signif-
icant association with hypercalciuria has been observed. All
these genetic studies tested a single gene and, due to this limi-
tation, their results cannot be considered definitive in the pre-
sence/absence of a genotype-phenotype correlation (13). Posi-
tive or negative results have to be reconsidered in function of
gene-gene and gene-environment interactions. 
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Figure 1 - Distribution of the values of calcium excretion in a population
of 471 patients with calcium kidney stone disease fits a bimodal model.
Analysis for mixture of distribution was performed with specific software
(5). The analysis considered the patients followed at outpatient’s clinic
for kidney stones at San Raffaele Hospital in Milan.
Figure 2 - Positive correlation between calcium excretion in parents and
offspring (upper part) and absence of correlation between spouses
(lower part) in 48 families living in Milan and villages near Milan. 
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Several genes accounting for Mendelian forms of PH, with or
without nephrocalcinosis, have been identified, such as Dent’s
disease, Bartter’s syndrome, familial hypomagnesaemia
hypocalciuria, familial hypocalcaemia hypercalciuria, familial
hypercalcaemia hypercalciuria, and some hypophosphatemic
syndromes. Unfortunately, their role in the pathogenesis of
sporadic forms of PH has to be clearly elucidated.
Candidate genes in familial and sporadic idiopathic renal
calcium stones/hypercalciuria
After identification of chromosomal localization of disease-gene
by linkage approach in kindreds affected by hypercalciuria
and/or calcium nephrolithiasis, many Authors also identified the
disease-causing gene itself, whose mutations have also been
evaluated in sporadic cases of PH. Hence, disease-causing
mutations and functional variants, namely polymorphisms, of
the same genes have been analyzed in order to detect the PH
susceptibility genotype. Due to no homogeneity of patients suf-
fering for PH and Idiopathic Nephrocalcinosis (ICN), subsets of
sporadic cases might be due to mutations or polymorphic vari-
ants in different candidate genes. However, up to now avail-
able results do not support the hypothesis that the described
gene mutations and polymorphisms have a significant role in
the majority of sporadic PH and ICN cases.
CLCN5 gene
C L C N 5 gene encodes for a chloride channel protein, expressed
in several human cells and in particular localized to the S3 seg-
ment of the proximal tubule and to medullary thick ascending
limb (mTAL). Subsequent subcellular fractionation studies indi-
cate that C L C N 5 is localized to endosomes (22) and it is impor-
tant for tubular reabsorption of low molecular weight proteins (1).
Several Mendelian CLCN5 gene mutations-depending pheno-
types have been described: X linked hypercalciuria nephrolithia-
sis, Dent’s disease, X linked recessive rickets, low molecular
weight proteinuria/nephrocalcinosis, Idiopathic nephrolithiasis, all
including PH (23). Frymoyer et al. (24) described a man with an
inactivating mutation in the C L C N 5 gene who did not have low
molecular weight proteinuria (together with the other features of
the Dent’s disease) and whose unique biochemical abnormality
was hypercalciuria (25). This raised the question as to whether
mutations in C L C N 5 gene might contribute to the phenotype in
patients with the diagnosis of PH, a condition that is twice as
common in males as in females suggesting that a subset of pa-
tients may have an X-linked transmission. Scheinmann et al.
(25) looked for CL C N 5 gene mutations in a group of 32/107 un-
related individuals (82 adults and 25 children) with PH. However,
PH was defined in a broad sense; this is meaningful in the
Dent’s condition where the mechanism of hypercalciuria includes
both excessive intestinal absorption of dietary calcium and fast-
ing hypercalciuria (26). No C LC N 5 gene mutation was observed
in this study and it is likely that Dent’s disease accounts for no
more than 3% of patients with sporadic form of PH. Gambaro et
al. recently performed C L C N 5 gene mutation analysis in dia-
lyzed patients with a personal history of calcium or radiopaque
stones and found no case of Dent’s disease confirming that this
disorder is really rare even in the pool of patients in which it
should be over-represented (Gambaro et al., unpublished).
NKCC2, ROMK, and CLCNKB genes
Mutations of these genes account for the highly genetic hetero-
geneous disorder represented by Bartter’s syndrome. This dis-
ease consists of a set of renal tubular disorders, inherited as
autosomal recessive trait, clinically characterized by chronic
hypokaliemia, metabolic alkalosis, hyperreninism and hyperal-
dosteronism with normal values of blood pressure: Antenatal
(with hyperproduction of type E Prostaglandins) and Classical
f rms of Bartter’s syndrome. PH is presented on both these
forms. Other additional biochemical and clinical features deter-
mine a different tubulopathies phenotype classification (27):
Antenatal form consists of type I, II and IV Bartter’s syndrome,
while Classical form is also indicated as type III Bartter’s syn-
drome (28). Mutations of the responsible genes create a se-
vere disturbance in maintaining the electric driving force at
tubular level regulating the paracellular transportation (from lu-
men to blood) of calcium.
NKCC2 gene. It encodes for the Na+/ K+/ C l2 co-transporter, a
membrane protein expressed on the lumen side of tubular cells
at TAL level, that physiologically determines the entry of the
above-described ions from lumen within the cell. Its mutations
have been reported in Antenatal Bartter’s syndrome preventing
the entry of Na+/K+/Cl2 from the lumen side (1).
ROMK gene. The encoded product of this gene is a potassium
channel protein whose function consists of recycling of K+, en-
tered through NKCC2, from intracellular store to the tubular lu-
men. It is essential for the function of NKCC2 itself. It has been
found mutated in Antenatal Bartter’s syndrome. Transfection
experiments of rat mutated R OM K - cDNA in COS-7 cells are
able to reduce or destroy the electrophysiological properties of
the channel-protein, preventing the K+recycling (29).
ClCNKB gene. It encodes for the human Chloride channel
(hClC-KB) (28) and its mutations alter the transportation, at the
basolateral membrane level, of the Chloride reabsorbed
through hClC-KB in the distal part of nephron (30, 31).
PCLN-1 gene-dependent hypercalciuric diseases
Familial Hypomagnesaemia with Hypercalciuria and Nephro-
calcinosis (FHHN) is a rare disorder of calcium and magnesium
paracellular transportation at TAL level depending on muta-
tions of P L C N - 1 gene. The gene product, paracellin-1 or
claudin, is essential in the regulation of the paracellular path-
way permeability at TAL level and its alteration determines a
d crease of calcium and magnesium reabsorption (32, 33). A
striking incidence of hypercalciuria, and nephrolithiasis among
f mily members not affected by FHHNC was observed by We-
ber et al in 13 of 23 families (33) and 11 cases (42%) out of 26
members of 4 affected families. In this study (33) most of the
non-FHHNC subjects presenting with hypercalciuria and/or
nephrolithiasis were obligate carriers of heterozygous PCLN-1
mutations. It seems therefore reasonable to propose a relation-
ship between sporadic hypercalciuria or stone disease and mu-
ta ions in the PCLN-1 gene. It might be expected that mutation
analysis of kindreds affected by familial hypercalciuria with
nephrocalcinosis and/or nephrolithiasis (with an apparently
dominant mode of inheritance) would demonstrate heterozy-
gous mutations in the PCLN-1 gene in some of them. Unfortu-
nately, this kind of study has yet to be performed. 
CaSR gene-dependent hypercalciuric diseases
C a S R gene activating mutations of the extracellular domain,
resulting in a gain of function, have been originally described to
be associated with hypocalcaemia in kindreds (34-36). Carling
et al. (37) recently described a kindred with 20 affected individ-
uals in whom the hypercalcemic trait segregated, in an autoso-
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mal dominant manner, with inappropriately higher serum PTH
and magnesium levels and urinary calcium levels than in unaf-
fected members. Presumably, the hypercalciuria in this family
may be secondary to the presence of hypercalcaemia due to
primary hyperparathyroidism.
Sequencing analysis identified an inactivating mutation with
substitution of phenylalanine to leucine at codon 881, located
in the cytoplasmic tail of the receptor and functional studies
demonstrated an inactivation of the receptor (37), probably
with a different functional capacity, in parathyroid and renal
cells, determining a more severe derangement in extracellular
C a2 +-sensing in the former (38,39). The hypothesis of implica-
tion of the C a S R gene in absorptive hypercalciuria (AH) and
calcium renal stones derives from the possibility that a mild
activation of the Ca S R could cause (in association with mild
hypocalcaemia) both the increased intestinal calcium absorp-
tion and calcium renal loss. Recently, a mechanism described
by Hebert et al (40) suggests that when at basolateral level
calcium concentrations are elevated, condition minimizing the
reabsorption, C a S R activation induces the inhibition of the
N a+/ K+/ C l– co-transporter, then inhibiting the electric force gra-
dient driving the paracellular transportation of Ca2 +from lumen
to blood (40). However, association studies in general popula-
tions have not corroborated this hypothesis. Indeed, Petrucci
et al (41) in a sib-pairs analysis in 359 French-Canadian stone
former subjects showed no significant association between
genetic variants of the C a S R gene and PH and ICN traits. Fur-
thermore, Lerolle et al. (42) failed to detect any mutation in the
seven coding exons of the C a S R gene in 9 families with PH,
renal stones and with a familial transmission consisting of au-
tosomal dominant inheritance. It is not possible to rule out that
mutations of the Ca S R gene could be found in some other
families or other populations, or that mutations of regulatory
regions of the gene may exist; nevertheless these findings in-
dicate that C a S R gene mutations do not represent a common
cause of familial PH. More recently, Vezzoli et al. (43) in an
Italian population case-control study, analyzing three clustered
Single Nucleotide Polymorphisms (SNPs) at exon 7 of C a S R
(G/T at codon 986, G/A at codon 990, and C/G at codon
1011), hypothesized a role for such variants in the physiologi-
cal regulation of the C a S R gene transcription levels, thus
identifying patients with increased relative risk for hypercalci-
uria/renal stones, according to specific clinical-biochemical
phenotypes. Such SNPs determine non-conservative amino
acid changes, which functional effects are still unknown, al-
though the importance of the allele 9 8 6 S e r and of the allele
9 9 0 G l y has been previously suggested according to lower
plasma levels of calcium in healthy people (44) and of PTH in
uremic patients (45), respectively. Thus, Vezzoli et al. (43)
suggested that the 9 9 0 G l y allele may increase the C a S R s e n-
sitivity or response to calcium ions, increasing inhibition of
PTH secretion, leading to lower calcium serum levels, in-
creased calciuria and bone turnover. According to this hypoth-
esis, this gene variant should correspond to an activating
SNP. However, C a S R gene cannot be considered as a major
gene involved in the pathogenesis of PH, representing only
one of the genetic components modulating the calcium excre-
tion. The minor contribution of the C a SR gene to calcium ex-
cretion could explain why no linkage was shown in the sib-pair
study carried out in Canada (41). 
NPT2a gene-dependent hypercalciuric diseases
Disorders of renal phosphate wasting may lead to hypophos-
phatemia, increase of 1,25(OH)2D3 and consequent excess of
intestinal calcium absorption and hypercalciuria. A clear exam-
ple is represented by Hereditary Hypophosphatemic Rickets
with Hypercalciuria (HHRH) (46), a phenotype similar, except
for bone, to that of mice with deletion of the kidney-specific
sodium-phosphate co-transporter gene, N p t 2. Mutational
analysis of human Npt2a gene has been performed by Prie et
al (47) identifying two patients (2 out of 20) carrying N P T 2 a
mutations, exhibiting urolithiasis or osteoporosis and persistent
idiopathic hypophosphatemia, associated with a decrease in
maximal renal phosphate reabsorption. Npt2a gene localizes at
chromosome 5q35. One of the 2 subjects was a man with re-
current renal stones, hypophosphatemia, and reduced renal
phosphate reabsorption; the second patient was a 64-year-old
woman with idiopathic bone demineralization, hypophos-
phatemia, and reduced renal phosphate reabsorption. Her only
daughter, who also had the mutation, had a spinal deformity
and a history of arm fractures, with hypophosphatemia and low
maximal renal phosphate reabsorption. NPT2a is a renal proxi-
mal tubular, brush-border membrane Na+-phosphate co-trans-
porter. Both NPT2a gene mutations (V147M and A48F) had a
dominant negative effect on the phosphate-induced current in
oocytes co-transfected with the wild and mutant RNAs. This
may explain why these mutations may lead to an impairment in
renal phosphate reabsorption, resulting in hypophosphatemia.
A low serum phosphate concentration, in turn, would be ex-
pected to increase 1,25-(OH)2D3 production (48, 49), leading to
increased intestinal absorption of calcium and hypercalciuria
(50). As mentioned above, this phenotype resembles that of
heterozygous N p t 2 a deficient mice, with increased urinary
p osphate and calcium excretion, elevated plasma concentra-
tions of 1,25-(OH)2D3 (51), and nephrocalcinosis (52). These
findings were consistent with a dominant negative effect of the
mutant proteins on the function of the wild type carrier, leading
to a substantial renal phosphate losses in heterozygous pa-
tients. However, as correctly pointed out by Scheinman and
Tenenhouse (53), this is at odds with the model with the target-
ed inactivation of Npt2 gene, where the heterozygous animals
have neither hypercalciuria nor nephrocalcinosis (54). The rea-
son why renal phosphate leak leads to either calcium stones or
bone demineralization is still unknown, although it might be due
to gender, environmental factors, or other genetic differences.
Although they did not search for mutations in introns or regula-
tory regions of the NPT2a gene, other genes may also be in-
volved in the renal phosphate leak in patients who did not dis-
close NPT2a gene mutations. The reported mother to daughter
mutation segregation suggests an autosomal dominant inheri-
tance, but up to date no systematic analysis of kindreds with
similar clinical phenotype has been performed.
“New” putative candidate genes
ECaC1 gene
Although no kindreds with familial hypercalciuria and/or renal
stones linked to the Epithelial Ca2 +channel 1 (E C a C 1) locus
have been reported so far, Muller et al (55) have looked for
E C a C 1 gene mutations in 9 families in which hypercalciuria
dominantly segregated. This channel has been recently iden-
tified: it allows the apical calcium entry step facilitating tran-
scellular calcium transport of the apical membranes of
1,25(OH)2D3-responsive epithelia in the kidney and small intes-
tine (56). It is a high selective channel that might play a crucial
role in Ca2 +-related disorders (57). The gene is on chromo-
some 7q35. The results from the Muller’s study were negative
and they did not support a primary role for the hECaC1 in the
pathogenesis of PH, but ECaC1 cannot be excluded as a can-
didate gene in other families with PH as the pathogenesis of
the disease is heterogeneous.
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Mutations in the genes responsible for distal renal tubular
acidosis (dRTA)
It is known that subtle forms of dRTA can occur only with hy-
percalciuria and recurrent calcium nephrolithiasis. Thus, it is
possible that the same molecular defects responsible for the
full range dRTA are also causative of cases of familial and spo-
radic forms of PH and ICN. As yet, both the ss1 subunit of the
vacuolar H+-ATPase (ATP6B1) and the carbonic anhydrase II
genes have not been investigated in sporadic and familial
forms of ICN. On the contrary the possible existence of a link-
age between the Anione Exchanger (A E1) locus and familial
ICN was the working hypothesis of a previous study of Gam-
baro et al. They formerly described the association of an anom-
alous erythrocyte oxalate self-exchange with ICN, dependent
on an abnormal phosphorylation of the AE1-band 3 exchanger
(58,59). Physiological and clinical studies showed the rele-
vance of this defect on ICN, and interestingly subclinical acidifi -
cation defects were disclosed in stone patients with the ery-
throcyte anomaly (59). In a family study, the abnormal erythro-
cyte oxalate self-exchange appeared to be genetically deter-
mined, segregating as a Mendelian autosomal dominant trait,
although polygenic inheritance could not be excluded (60).
However, a linkage analysis between the 17q21-qter loci, con-
taining the AE1 gene and the abnormal oxalate self-exchange,
in 2 of three-generation families with renal stones was negative
(61). Thus, the suggested hypothesis is that the erythrocyte ox-
alate self-exchange is an intermediate phenotype, possibly with
a polygenic determination.
Conclusions
As discussed, the frequencies of dominant and recessive re-
nal-stone-related conditions are uncommon to rare, reflecting
the rarity of mutated genes producing them. In these disorders
the inheritance of one or a couple of defective alleles is neces-
sary and sufficient to induce the disease in the absence of any
particular environmental factors. In polygenic diseases the indi-
vidual genes by per seare not capable to cause the disease;
but individual environmental factors are also incapable to de-
termine the disease. However, individual genes and environ-
mental factors, in various combinations, account for common
types of calcium nephrolithiasis. We have already discussed
that mutations of genes involved in monogenic disorders were
not found in sporadic idiopathic stone formers. However, a pos-
sible explanation is that some of candidate, and still unknown
genes, have to be analyzed in this regard; alternatively, only a
small subset of PH and ICN patients has a Mendelian disorder.
Similar considerations suggest the possibility that mutations in
the A E 1 gene or in the ATP6B1 gene which have been de-
scribed in recessive forms of dRTA are responsible for spo-
radic PH and ICN. Subtle defects in renal acidification, and
hypocitraturia, in some cases markers of mild form of dRTA,
are too much frequently observed in idiopathic patients. On the
contrary, familial dRTA, particularly the recessive forms, are
extremely rare conditions. An autosomal dominant inheritance
has also been suggested in families with PH (both the absorp-
tive and renal types) and calcium renal stone forming subjects
(62). However, since in as high as 55-60% of index cases
(probands) no other case can be recognized in the family, un-
der the hypothesis that hypercalciuria is an autosomal disorder
it is very unlikely that a mutation occurs in 50% of hypercalci-
uric subjects. That possibility would require a new mutation
rate greater than observed in humans. On the other hand, by
excluding probands from the analysis of these observations,
the proportion of hypercalciuric siblings decreases to value as
low as 10%, a proportion very far from expected in a case of an
autosomal dominant inheritance (63). A polygenic model of in-
heritance of renal stones was proposed by Resnick et al (64)
based on the observation that there is a higher proportion of af-
fected younger siblings in which one of two oldest siblings is af-
fected than when both are unaffected. Several Authors have al-
ready noted that some of the quantitative traits encountered in
idiopathic calcium stone formers have a normal distribution
with no evidence for bimodal distribution; as observed for the
renal phosphate threshold and hypophosphatemia and for cal-
ciuria. These findings suggest that the biochemical phenotypes
encountered in PH and ICN are complex traits controlled by
multiple factors (social, cultural, environmental, dietary, etc.),
and multiple genes. The complexity of this apparently simple
and clear statement is huge and generated by difficulties in dis-
secting non-hereditary from hereditary factors. This is the real
gamble in grasping complex diseases. The genetic component
of complex, polygenic diseases as PH and ICN may become
evident only through a careful control of non-hereditary factors.
Dietary habits of stone formers compared with nonstone form-
ers are very similar (63), indirectly suggesting that part of the
variability in stone-related traits is genetically raised; moreover,
investigation of a cohort of 101 normal subjects under self-se-
lected, controlled and formula diets provided the development
of a computer model showing that with only three genes a pat-
tern of inheritance is generated, simulating the observed inheri-
tance in ICN in the population and among relatives of stone for-
mers. This certainly is an oversimplification, but it is a clear
demonstration that the idiopathic renal stone disease is a poly-
genic disorder. Indeed, we have no idea about the number of
genes predisposing to hypercalciuria and calcium stone forma-
tion.Furthermore, we do know neither whether among several
genes one or few genes play a major role, nor whether differ-
ent degrees of risk are associated with each locus.
Larger population studies have to be performed, and environ-
mental factors, particularly nutrients, have to be accurately
evaluated together with complex genotyping in order to esta-
blish their importance in masking/unmasking functional variants
correlated to specific genetic background and to create more
effective preventive strategies for PH and ICN. Accurate stan-
dardized phenotype definitions are needed to add a more pow-
erful statistical value to family-base studies. Comparative ge-
netics will add informations on potentially interesting genes in
humans once quantitative traits in animal models are identified.
Great results are expected from development of new DNA mi-
croarray and bioinformatic technologies not only for gene vari-
ants detection, but also for “proteomic and metabolomic” as-
pects of the pathogenesis of PH and ICN, providing new oppor-
tunities to identify individuals at risk for these disorders and to
develop new tailored therapies by newly designed clinical trial
involving less genetically unselected individuals, creating also
the opportunity of avoiding/reducing severe side effects.
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